Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Refresh Optive® Gel Drops
Refresh Optive · 1 trial · 1 indication
The OSDI is a 12-question survey for patients to document their dry eye disease symptoms. The OSDI consists of a 5-point scale (0=none of the time and 4=all of the time), with higher scores representing greater disability. The scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability). A negative number change from baseline represents an improvement.
| Arm | Type | Description |
|---|---|---|
| Refresh Optive® Gel Drops | EXPERIMENTAL | Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days. |
| REFRESH LIQUIGEL® | ACTIVE_COMPARATOR | REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days. |
| Name | Type | Description |
|---|---|---|
| Refresh Optive® Gel Drops | DRUG | Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days. |
| REFRESH LIQUIGEL® | DRUG | REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days. |
Inclusion Criteria: * Current use of an artificial tear product * Visual acuity of at least 20/32 (while wearing glasses, if necessary). Exclusion Criteria: * Use of contact lenses in the last 3 months, or anticipated use of contact lenses during the study * Cataract surgery, laser-assisted in si...
Top 20 of 33 competitors
Refresh Optive is used for dry eye syndromes, a group of conditions in which the eyes do not produce enough tears or tears evaporate too quickly. It is an ophthalmology product developed by AbbVie Inc. under ticker ABBV. A Phase 3 study evaluated it in patients with dry eye disease.
Refresh Optive is developed by AbbVie Inc., which trades under the ticker ABBV. AbbVie is the company behind the Refresh Optive program in ophthalmology, and it sponsored the Phase 3 clinical study of Refresh Optive Gel Drops in patients with dry eye disease.
Refresh Optive is in Phase 3 development. One Phase 3 trial has been completed, and no trials are currently active. The completed study was a randomized, double-blind, active-controlled trial that enrolled 188 patients with dry eye disease in the United States.
Refresh Optive has been studied in one Phase 3 trial, NCT02280473, titled A Safety and Efficacy Study of Refresh Optive Gel Drops in Patients With Dry Eye Disease. It was a completed, randomized, double-blind, active-controlled study that enrolled 188 participants aged 18 years and older in the United States.
Yes, Refresh Optive is also known as Refresh Optive Gel Drops. The alternative name appears with the registered trademark symbol as Refresh Optive® Gel Drops. Both names refer to the same AbbVie ophthalmology product studied in dry eye disease under the Phase 3 trial NCT02280473.